STOCKHOLM – April 19, 2013. Pergamum AB announced today that the company has reached last-patient-last-visit (LPLV) in a randomized Phase I/II trial of LL-37 for the treatment of hard-to-heal venous leg ulcers. Karolinska Development AB is the majority owner of…
MoreNews
Pergamum appoints Ernst & Young as a strategic advisor
STOCKHOLM – April 9, 2013. Pergamum AB announced today that the company has signed an agreement with Ernst & Young to serve as a strategic advisor in the search for an acquirer or strategic partner. Pergamum is part of the…
MorePergamum AB Announces a Strategic Collaboration with Cadila Pharmaceuticals Ltd
STOCKHOLM, SWEDEN – February 8, 2013. Pergamum AB and Cadila Pharmaceuticals Ltd today announced a strategic collaboration to develop a novel treatment of infections with a unique targeting mechanism clearly distinguished from classical antibiotics. Pergamum is part of the Karolinska…
MorePergamum Reports Positive Phase II Data from Clinical Trial in Outer Ear Infections
STOCKHOLM – December 21, 2012. Pergamum AB announced today that the primary endpoint was met in the randomized Phase II trial of DPK-060 for treatment of acute external otitis. Karolinska Development AB is the majority owner of Pergamum AB. “The…
MorePergamum Announces That The First Patient Has Been Dosed with Potential New Treatment for Hard-to-Heal Wounds
STOCKHOLM – September 11, 2012. Pergamum AB announced today that dosing has begun in a randomized Phase I/II trial of its drug candidate LL-37 for the treatment of patients with hard-to-heal venous leg ulcers. Karolinska Development AB is the majority…
MorePergamum reports top line Phase II-data from the clinical trial for prevention of post-surgical adhesions
SWEDEN, STOCKHOLM – July 10, 2012. Pergamum AB, a Karolinska Development portfolio company, today announced top-line results from the randomized first time in patient Phase II trial of PXL-01 for prevention of post-surgical adhesions. The study showed that the drug…
MoreMargit Mahlapuu Appointed as CSO of Pergamum AB
SWEDEN, STOCKHOLM – 2 May, 2012. Pergamum AB today announced that Dr. Margit Mahlapuu was appointed as the company’s Chief Scientific Officer (CSO). Pergamum AB was formed in 2009 with the objective of synergetically aggregating a number of programs in…
MorePergamum Completes Patient Recruitment to the Phase II Clinical Trial for Prevention of Post-Surgical Adhesions
SWEDEN, STOCKHOLM – February 10, 2012. Pergamum AB announced today that the last patient has been dosed in a randomized Phase II trial of PXL01 for prevention of postsurgical adhesions. Karolinska Development AB is the majority owner of Pergamum. In…
More